Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 272

1.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants.

Kidney Int. 2019 Apr 30. pii: S0085-2538(19)30276-5. doi: 10.1016/j.kint.2019.02.022. [Epub ahead of print]

PMID:
31053387
2.

Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, Perkovic V, Sarnak MJ, Tobe SW, Tomson CRV, Cheung M, Wheeler DC, Winkelmayer WC, Mann JFE; Conference Participants.

Kidney Int. 2019 May;95(5):1027-1036. doi: 10.1016/j.kint.2018.12.025.

PMID:
31010478
3.

Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.

Lamina C, Kronenberg F, Stenvinkel P, Froissart M, Forer L, Schönherr S, Wheeler DC, Eckardt KU, Floege J.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz060. doi: 10.1093/ndt/gfz060. [Epub ahead of print]

PMID:
31006013
4.

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Idzerda NMA, Stefansson BV, Pena MJ, Sjostrom DC, Wheeler DC, Heerspink HJL.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz064. doi: 10.1093/ndt/gfz064. [Epub ahead of print]

PMID:
31005993
5.

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray MJ, Gray A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int. 2019 Mar 12. pii: S0085-2538(19)30171-1. doi: 10.1016/j.kint.2019.01.028. [Epub ahead of print]

PMID:
31005271
6.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.

PMID:
30992195
7.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
8.

Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Chan CT, Blankestijn PJ, Dember LM, Gallieni M, Harris DCH, Lok CE, Mehrotra R, Stevens PE, Wang AY, Cheung M, Wheeler DC, Winkelmayer WC, Pollock CA; Conference Participants.

Kidney Int. 2019 Apr 12. pii: S0085-2538(19)30138-3. doi: 10.1016/j.kint.2019.01.017. [Epub ahead of print]

PMID:
30987837
9.

The impact of an insecticide treated bednet campaign on all-cause child mortality: A geospatial impact evaluation from the Democratic Republic of Congo.

Dolan CB, BenYishay A, Grépin KA, Tanner JC, Kimmel AD, Wheeler DC, McCord GC.

PLoS One. 2019 Feb 22;14(2):e0212890. doi: 10.1371/journal.pone.0212890. eCollection 2019.

10.

Spatial Analysis of the Impact of a School-Level Youth Violence Prevention Program on Violent Crime Incidents in the Community.

Masho SW, Zirkle KW, Wheeler DC, Sullivan T, Farrell AD.

Prev Sci. 2019 May;20(4):521-531. doi: 10.1007/s11121-019-0990-1.

PMID:
30719615
11.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

12.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
13.

Prevalence and Characteristics of Pediatric Opioid Exposures and Poisonings in the United States.

Patel AM, Wheeler DC, Rose SR, Nadpara PA, Pakyz AL, Carroll NV.

J Pediatr. 2019 Mar;206:148-155.e4. doi: 10.1016/j.jpeds.2018.10.047. Epub 2019 Jan 4.

PMID:
30612813
14.

New pharmacological strategies for protecting kidney function in type 2 diabetes.

Muskiet MHA, Wheeler DC, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 May;7(5):397-412. doi: 10.1016/S2213-8587(18)30263-8. Epub 2018 Dec 19. Review. Erratum in: Lancet Diabetes Endocrinol. 2019 Feb 4;:.

PMID:
30579729
15.

Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.

Verberne WR, Das-Gupta Z, Allegretti AS, Bart HAJ, van Biesen W, García-García G, Gibbons E, Parra E, Hemmelder MH, Jager KJ, Ketteler M, Roberts C, Al Rohani M, Salt MJ, Stopper A, Terkivatan T, Tuttle KR, Yang CW, Wheeler DC, Bos WJW.

Am J Kidney Dis. 2019 Mar;73(3):372-384. doi: 10.1053/j.ajkd.2018.10.007. Epub 2018 Dec 20.

16.

Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.

Roep BO, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74. doi: 10.1016/S2213-8587(18)30109-8. Epub 2018 Oct 24. Review.

PMID:
30528100
17.

The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. doi: 10.1016/S2213-8587(18)30112-8. Epub 2018 Oct 24. Review.

PMID:
30528099
18.

Modeling groundwater nitrate exposure in private wells of North Carolina for the Agricultural Health Study.

Messier KP, Wheeler DC, Flory AR, Jones RR, Patel D, Nolan BT, Ward MH.

Sci Total Environ. 2019 Mar 10;655:512-519. doi: 10.1016/j.scitotenv.2018.11.022. Epub 2018 Nov 5.

PMID:
30476830
19.

Erratum: Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625-637.

Chronic Kidney Disease Prognosis Consortium.

Kidney Int Rep. 2018 Aug 30;3(6):1506. doi: 10.1016/j.ekir.2018.08.009. eCollection 2018 Nov.

20.

Spatial analysis of the relative risk of suicide for Virginia counties incorporating uncertainty of variable estimates.

Orndahl CM, Wheeler DC.

Spat Spatiotemporal Epidemiol. 2018 Nov;27:71-83. doi: 10.1016/j.sste.2018.10.001. Epub 2018 Oct 13.

PMID:
30409378

Supplemental Content

Loading ...
Support Center